Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94200Research ArticleNefroprotektivnye svoystva antagonistov kal'tsiya: rol' lerkanidipinaRudenkoT. E-KutyrinaI. M-1505201416512312628122021Copyright © 2014, Consilium Medicum2014хроническая болезнь почексахарный диабетсосудистые осложненияартериальная гипертензияблокаторы кальциевых каналовлерканидипин[Швецов М.Ю. Современные принципы диагностики и лечения болезни почек. Методич. руководство для врачей. Коломна, 2010.][Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16 (1): 89-115.][Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 (Suppl. 5): 69-80.][Кутырина И.М., Швецов М.Ю. Возможности лечения почечной артериальной гипертонии. Качество жизни. Медицина. 2006; 4 (15): 78-89.][Бобкова И.Н. Клеточно - молекулярные механизмы нефротоксического действия протеинурии: роль в прогрессировании хронического гломерулонефрита, пути воздействия. Автореф. дис. ... д - ра мед. наук. М., 2007.][Руденко Т.Е., Кутырина И.М., Швецов М.Ю. Состояние липидного обмена при хронической болезни почек. Клин. нефрология. 2012; 2: 14-21.][Нефрология: национальное руководство под ред. Н.А.Мухина. М.: ГЭОТАР-Медиа, 2009.][Мухин Н.А., Козловская Л.В., Шилов Е.М. Рациональная фармакотерапия в нефрологии. Руководство для практикующих врачей. М.: Литтерра, 2006.][Herbette L, Vecchiarelly M, Leonardi A et al. Lercanidipine: short plasma half - life, long duration of action. J Cardiovasc Pharmacol 1997; 29 (Suppl. 1): S19-24.][Angelico P, Guarneri L, Leonardi A et al. Vascular - selective effect of lercanidipine and other1,4-dihydropyridines in isolated rabbit tissues. J Pharm Pharmacol 1998; 51: 709-14.][Macchiarulo C, Pieri R, Mitolo D.C et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): 236-53.][Bianchi G, Passoni A, Griffini P.L et al. Effects of a new calcium antagonist, Rec 15/2375 on cardiac contractility of conscious rabbits. Pharmacol Res 1989; 21 (2): 193-200.][Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): 95-100.][Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient preference and adherence 2012; 6: 449-55.][Barbagallo M, Barbagallo S.G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12: 375-9.][Dalla Vestra M, Pozza G, Mosca A. Effect of lercanidipine compared with ramipril on albumine excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL Study (Diabete, Ipertension, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259-66.][Herrera J, Ghais Z, Gonzalez L. Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting [abstract]. J Hypertens 2002; 20 (Suppl. 4): S162.][Sabbatini M, Leonardi A, Testa R et al. Effects of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertens 2000; 35: 775-9.][Sabbatini M, Vitaioli L, Baldony E, Amenta F. Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats. JPET 2000; 294: 248-54.][Sabbatini M, Leonardi A, Testa R et al. Effects of dihydropyridini - type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2002; 39: 39-48.][Robles N.R, Ocon J, Gomez C.F et al. Lercanidipine in patients with chronic renal failure: the ZAFRA Study. Renal Failure 2005; 1: 73-80.][Robles N.R, Romero B, de Vinuesa E.G et al. Treatment of proteinuria with lercanidipine associated with renin - angiotensin axis - blocking drugs. Renal Failure 2010; 32: 192-7.][Martinez M.L, Castro M.M, Rizzi E et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rate. Int J Clin Pract 2008: 65 (2): 723-8.][Wu J.R, Liou S.F, Lin S.W et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellurlar reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59 (1): 48-56.][Sironi G, Colombo D, Greto L et al. Regional vasodilating effect of lercanidipine in dogs. ISHR XVI World Congress, 1998.][Sabbatini M, Tomassoni D, Amenta P. Influence of effect of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001; 122 (8): 795-809.][De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32 (2): 565-74.]